ESC 2024 - To date, there have been 5 large RCTs investigating whether timing of antihypertensive medication has an effect on the risk of MACE. Ricky Turgeon shares the results of a meta-analysis of these 5 trials.
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
ESC 2024 - To date, there have been 5 large RCTs investigating whether timing of antihypertensive medication has an effect on the risk of MACE. Ricky Turgeon shares the results of a meta-analysis of these 5 trials.
This video was recorded during the ESC Congress 2024 in London, UK.
Ricky Turgeon is an assistant professor at the Faculty of Pharmaceutical Sciences at University British Colombia in Vancouver, BC, Canada.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of this meta-analysis
Release date: 31 August 2024
ESC 2024 - To date, there have been 5 large RCTs investigating whether timing of antihypertensive medication has an effect on the risk of MACE. Ricky Turgeon shares the results of a meta-analysis of these 5 trials.
This video was recorded during the ESC Congress 2024 in London, UK.
Ricky Turgeon is an assistant professor at the Faculty of Pharmaceutical Sciences at University British Colombia in Vancouver, BC, Canada.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of this meta-analysis
Release date: 31 August 2024
Stay current with the best on medical education
